J&J taps in­to BAR­DA well a third time to speed up its PhI­II Covid-19 vac­cine tri­al

BAR­DA is pour­ing $454 mil­lion more in­to John­son & John­son’s Covid-19 vac­cine ef­forts, as the phar­ma huffs and puffs to catch up with fast-mov­ing fron­trun­ners Pfiz­er/BioN­Tech and Mod­er­na.

Janssen, the J&J sub­sidiary de­vel­op­ing the vac­cine can­di­date, has al­ready re­ceived over $1.4 bil­lion from the HHS de­part­ment. Un­der the ex­pand­ed agree­ment, BAR­DA will kick in an­oth­er $454 mil­lion to sup­port the com­pa­ny’s 60,000-per­son Phase III tri­al, and J&J will com­mit an­oth­er $604 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.